Related Experiment Video
Updated: Jun 20, 2026
11:49
Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model
Published on: September 9, 2011
Endothelial progenitor cells, late stent thrombosis and delayed re-endothelialisation
Rohit Khurana1, Manuel Mayr, Jonathan M Hill
1Department of Cardiology, King's College Hospital, Denmark Hill, London, United Kingdom.
Summary
Endothelial progenitor cells (EPCs) play a crucial role in vascular health and disease, particularly in coronary artery disease. This review explores EPC phenotypes, their link to heart disease risk factors, and strategies to improve EPC function.
Area of Science:
- Vascular Biology
- Cell Biology
- Regenerative Medicine
Background:
- Endothelial progenitor cells (EPCs) emerged a decade ago, defined by their ability to differentiate into mature endothelial cells and integrate into sites of angiogenesis.
- EPC biology has significantly advanced understanding of vascular abnormalities in diverse diseases, including pre-eclampsia, pulmonary hypertension, and cancer.
- The impact of EPC discovery is most profound in coronary artery disease, influencing both basic pathophysiology and clinical applications.
Purpose of the Study:
- To review current knowledge of EPC phenotypes and their association with coronary artery disease risk factors.
- To examine the consequences of EPC dysfunction on percutaneous coronary interventions.
- To discuss therapeutic strategies, including pharmacological and stent-based approaches, aimed at enhancing EPC number and function.
Main Methods:
- Review of existing literature on endothelial progenitor cells.
- Analysis of the relationship between EPC phenotypes and coronary artery disease risk factors.
- Evaluation of EPC dysfunction in the context of percutaneous interventions.
- Assessment of current and potential therapeutic strategies for modulating EPCs.
Main Results:
- EPCs are integral to vascular repair and implicated in numerous diseases.
- EPC dysfunction is linked to increased cardiovascular risk and poorer outcomes after interventions.
- Pharmacological and stent-based strategies show promise for augmenting EPC function.
Conclusions:
- EPCs are critical players in cardiovascular health and disease.
- Understanding EPC phenotypes and function is key to developing novel diagnostics and therapeutics for coronary artery disease.
- Targeting EPCs offers a promising avenue for improving outcomes in patients with cardiovascular conditions.
More Related Videos
Related Concept Videos
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:16Vascular Spasm
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...